|
Jul 1
|
FDA approves Takeda’s Gammagard liquid ERC for primary immunodeficiency
|
|
Jun 30
|
Takeda Announces U.S. FDA Approval of GAMMAGARD LIQUID ERC, the Only Ready-to-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content1
|
|
Jun 27
|
Tempus AI's Data Business Keeps Scaling Up: Can the Growth Pace Last?
|
|
Jun 27
|
Will Strong Asceniv Sales Drive ADMA Biologics Further?
|
|
Jun 25
|
Liver Organoid Breakthrough: Generating Organ-Specific Blood Vessels
|
|
Jun 25
|
Ocular Therapeutix (OCUL) Moves 8.6% Higher: Will This Strength Last?
|
|
Jun 25
|
ADMA vs Takeda: Which Plasma Therapy Stock Is the Better Buy Today?
|
|
Jun 25
|
Takeda Announces New Assignments of Directors
|
|
Jun 4
|
EC approves Takeda ADC plus chemo for stage IIb Hodgkin’s lymphoma
|
|
Jun 3
|
European Commission Approves ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Newly Diagnosed Stage IIb/III/IV Hodgkin Lymphoma in Combination with ECADD
|
|
Jun 1
|
Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera
|
|
May 27
|
Xoma Royalty Acquires Mezagitamab Royalty, Milestone Rights From BioInvent
|
|
May 27
|
Takeda and Nature Announce Call for Applications Now Open for 2026 Innovators in Science Award
|
|
Apr 11
|
NMPA approves BBM and Takeda China’s haemophilia B therapy
|
|
Apr 9
|
Pharma Stocks Slide Further After Trump Reiterates Tariff Threats on Drugs
|
|
Apr 4
|
Is Takeda Pharmaceutical Co. (TAK) Stock Undervalued Right Now?
|
|
Mar 14
|
TAK or DSNKY: Which Is the Better Value Stock Right Now?
|
|
Mar 13
|
Takeda’s $770M deal deepens Big Pharma’s omics push
|
|
Mar 3
|
Takeda-Protagonist Therapeutics Partnered Investigational Drug Hits Primary Goal In Late-Stage Study In Patients With Type Of Blood Cancer
|
|
Mar 3
|
Takeda and Protagonist report topline outcomes from trial of rusfertide
|